[
  {
    "ts": null,
    "headline": "Agilent Technologies Inc. stock outperforms competitors on strong trading day",
    "summary": "Agilent Technologies Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3b12aaf49a1ce24e85d0ef0dc707710008d74b45eddf56c6eb62c0794720a1fb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750784160,
      "headline": "Agilent Technologies Inc. stock outperforms competitors on strong trading day",
      "id": 135551744,
      "image": "",
      "related": "A",
      "source": "MarketWatch",
      "summary": "Agilent Technologies Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3b12aaf49a1ce24e85d0ef0dc707710008d74b45eddf56c6eb62c0794720a1fb"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Agilent’s Q1 Earnings Call",
    "summary": "Agilent’s second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase",
    "url": "https://finnhub.io/api/news?id=116196d325cd204d0f37cfd8500a868710b68b22fb0e75abd3b1a57368053d54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750743608,
      "headline": "The 5 Most Interesting Analyst Questions From Agilent’s Q1 Earnings Call",
      "id": 135514161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "Agilent’s second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase",
      "url": "https://finnhub.io/api/news?id=116196d325cd204d0f37cfd8500a868710b68b22fb0e75abd3b1a57368053d54"
    }
  }
]